Victoza overview
Brand name for liraglutide 1.8 mg daily, FDA-approved for type 2 diabetes mellitus.
Victoza at a glance
Related pages
- Clinical research overview
- Compare GLP-1 forms
- Compounded vs brand
- NexLife (highest v4.1 score)
Key facts, checked November 20, 2026
The Victoza label covers blood-sugar control in patients 10 and older with type 2 diabetes and lowering the risk of major cardiovascular events in adults with type 2 diabetes and established heart disease. It is a once-daily liraglutide injection and should not be used for type 1 diabetes. The weight-management form of liraglutide is Saxenda, at a higher dose. FDA drug-shortage data (openFDA) list liraglutide injection as in shortage, with an update dated October 14, 2026. FDA’s November 9, 2026 safety communication adds a NAION warning to all approved GLP-1 labels.